Recombinant Pyrococcus furiosus albA Protein ，His & SUMO

AlbA, an albumin-binding protein, has garnered significant attention in the field of biomedical research due to its unique properties and potential applications. Initially discovered in *Bacillus subtilis*, AlbA is known for its ability to bind to human serum albumin, a prevalent protein in the bloodstream with numerous physiological roles. Studies have revealed that AlbA can enhance the solubility and stability of various therapeutic proteins, making it a valuable tool in drug delivery systems. Researchers are particularly interested in its role in improving the pharmacokinetics of drugs, allowing for prolonged circulation time and reduced dosage frequency, which can lead to improved patient compliance and therapeutic outcomes. Moreover, the engineering of AlbA for targeted drug delivery holds promise in oncological applications, where localized therapy is crucial for minimizing side effects. The exploration of AlbA’s structure-function relationship also provides insights into protein-protein interactions that are fundamental to many biological processes. Recent advances in recombinant DNA technology have enabled the production of AlbA in various host systems, facilitating extensive studies into its functionality and interaction mechanisms. Overall, the ongoing research on AlbA not only contributes to the understanding of protein behavior in biological systems but also paves the way for innovative strategies in drug formulation and delivery, with the potential to transform treatment paradigms for various diseases.